ArticlePharmacoEconomics2016
Biosimilars: How Can Payers Get Long-Term Savings?
Article in PharmacoEconomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.Arthritis research & therapy · 2016Trial
- Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis.PharmacoEconomics - open · 2026Article
- Individual Prescribing Incentives for Biosimilars in Selected European Countries and the USA: a Scoping Literature Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- Cost-Effective and Sustainable Drug Use in Hospitals: A Systematic and Practice-Based Approach.Applied health economics and health policy · 2025Article
- The impact of an 'evergreening' strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Unveiling the Biosimilar Paradox of Oncologists' Perceptions and Hesitations in South Korea: A Web-Based Survey Study.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Article
- Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Article
- Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Article
- Biosimilars in Oncology: Latest Trends and Regulatory Status.Pharmaceutics · 2022Review
- Awareness and Knowledge of Pharmacists toward Biosimilar Medicines: A Survey in Jordan.International journal of clinical practice · 2022Article
- Estimating Potential for Drug Budget Reallocation Following Expiration of Exclusivity of Pharmaceutical Products.Journal of health economics and outcomes research · 2022Article
- Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States.Journal of managed care & specialty pharmacy · 2021Article
- Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria.Healthcare (Basel, Switzerland) · 2021Article
- Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.Frontiers in pharmacology · 2021Article
- Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Sustainability of costs of novel biologicals: Are we all heading for bankruptcy?British journal of clinical pharmacology · 2020Article
- Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany.International journal of environmental research and public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term 'biosimilar' refers to an alternative similar version of an off-patent innovative originator biotechnology product (the 'reference product'). Several biosimilars have been approved in Europe, and a number of top-selling biological medicines have lost, or will lose, patent protection over the next 5 years. We look at the experience in Europe so far. The USA has finally implemented a regulatory route for biosimilar approval. We recommend that European and US governments and payers take a strategic approach to get value for money from the use of biosimilars by (1) supporting and incentivising generation of high-quality comprehensive outcomes data on the effectiveness and safety of biosimilars and originator products; and (2) ensuring that incentives are in place for budget holders to benefit from price competition. This may create greater willingness on the part of budget holders and clinicians to use biosimilar and originator products with comparable outcomes interchangeably, and may drive down prices. Other options, such as direct price cuts for originator products or substitution rules without outcomes data, are likely to discourage biosimilar entry. With such approaches, governments may achieve a one-off cut in originator prices but may put at risk the creation of a more competitive market that would, in time, produce much greater savings. It was the creation of competitive markets for chemical generic drugs-notably, in the USA, the UK and Germany-rather than price control, that enabled payers to achieve the high discounts now taken for granted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.